Genome-wide association study of plasma efavirenz pharmacokinetics in AIDS Clinical Trials Group protocols implicates several CYP2B6 variants - Wikidata - wikimedia - TriplyDB

Genome-wide association study of plasma efavirenz pharmacokinetics in AIDS Clinical Trials Group protocols implicates several CYP2B6 variants

Genome-wide association study of plasma efavirenz pharmacokinetics in AIDS Clinical Trials Group protocols implicates several CYP2B6 variants

http://www.wikidata.org/entity/Q36734592

about

Perspectives on pharmacogenomics of antiretroviral medications and HIV-associated comorbidities Efavirenz and the CNS: what we already know and questions that need to be answered PHENOME-WIDE INTERACTION STUDY (PheWIS) IN AIDS CLINICAL TRIALS GROUP DATA (ACTG).Evaluation of an immunoassay for determination of plasma efavirenz concentrations in resource-limited settings.Functional CYP2B6 variants and virologic response to an efavirenz-containing regimen in Port-au-Prince, Haiti.Secondary metabolism pathway polymorphisms and plasma efavirenz concentrations in HIV-infected adults with CYP2B6 slow metabolizer genotypes.Phase I safety, pharmacokinetics, and pharmacogenetics study of the antituberculosis drug PA-824 with concomitant lopinavir-ritonavir, efavirenz, or rifampin.Sensitive assessment of the virologic outcomes of stopping and restarting non-nucleoside reverse transcriptase inhibitor-based antiretroviral therapy.Pharmacogenomics of antimicrobial agents.Pharmacokinetics of efavirenz and treatment of HIV-1 among pregnant women with and without tuberculosis coinfection.Genome-wide association study of virologic response with efavirenz-containing or abacavir-containing regimens in AIDS clinical trials group protocols.Phenome-wide Association Study Relating Pretreatment Laboratory Parameters With Human Genetic Variants in AIDS Clinical Trials Group Protocols.Population pharmacogenetic-based pharmacokinetic modeling of efavirenz, 7-hydroxy- and 8-hydroxyefavirenz.PharmGKB summary: Efavirenz pathway, pharmacokinetics A Global Health Diagnostic for Personalized Medicine in Resource-Constrained World Settings: A Simple PCR-RFLP Method for Genotyping CYP2B6 g.15582C>T and Science and Policy Relevance for Optimal Use of Antiretroviral Drug Efavirenz.Pharmacogenetics of plasma efavirenz exposure in HIV-infected adults and children in South Africa.Genomewide association study of tenofovir pharmacokinetics and creatinine clearance in AIDS Clinical Trials Group protocol A5202 Case report: Severe central nervous system manifestations associated with aberrant efavirenz metabolism in children: the role of CYP2B6 genetic variation.Combined effect of CYP2B6 and NAT2 genotype on plasma efavirenz exposure during rifampin-based antituberculosis therapy in the STRIDE study Pharmacogenomics Implications of Using Herbal Medicinal Plants on African Populations in Health Transition Plasma nevirapine concentrations predict virological and adherence failure in Kenyan HIV-1 infected patients with extensive antiretroviral treatment exposure An Expanded Analysis of Pharmacogenetics Determinants of Efavirenz Response that Includes 3'-UTR Single Nucleotide Polymorphisms among Black South African HIV/AIDS Patients Treatment Failure, Drug Resistance, and CD4 T-Cell Count Decline Among Postpartum Women on Antiretroviral Therapy in South Africa Plasma Efavirenz Concentrations Are Associated With Lipid and Glucose Concentrations.Pharmacokinetic and Pharmacodynamic Comparison of Once-Daily Efavirenz (400 mg vs. 600 mg) in Treatment-Naïve HIV-Infected Patients: Results of the ENCORE1 Study.Multiple genetic variants predict steady-state nevirapine clearance in HIV-infected Cambodians.Pharmacogenetics of cytochrome P450 2B6 (CYP2B6): advances on polymorphisms, mechanisms, and clinical relevance Methadone N-demethylation by the common CYP2B6 allelic variant CYP2B6.6.Cost-effectiveness of CYP2B6 genotyping to optimize efavirenz dosing in HIV clinical practice.CYP2B6*6 and CYP2B6*18 Predict Long-Term Efavirenz Exposure Measured in Hair Samples in HIV-Positive South African Women Comprehensive Pharmacokinetic, Pharmacodynamic and Pharmacogenetic Evaluation of Once-Daily Efavirenz 400 and 600 mg in Treatment-Naïve HIV-Infected Patients at 96 Weeks: Results of the ENCORE1 Study The impact of genetic polymorphisms on the pharmacokinetics of efavirenz in African children Relationship between weight, efavirenz exposure, and virologic suppression in HIV-infected patients on rifampin-based tuberculosis treatment in the AIDS Clinical Trials Group A5221 STRIDE Study.Clinical and genetic determinants of plasma nevirapine exposure following an intrapartum dose to prevent mother-to-child HIV transmission Effects of rifampin-based antituberculosis therapy on plasma efavirenz concentrations in children vary by CYP2B6 genotype.Multiphenotype association study of patients randomized to initiate antiretroviral regimens in AIDS Clinical Trials Group protocol A5202.Neuronal toxicity of efavirenz: a systematic review.Cytochrome P450 pharmacogenetics in African populations: implications for public health.Pharmacogenetic considerations in the treatment of HIV.Effect of rifampicin and efavirenz on moxifloxacin concentrations when co-administered in patients with drug-susceptible TB.

P2860

Q26853274-1B0349C6-DFC8-4D99-9A97-0BCCBE5FAEBE Q28085028-DD0252C5-FF7D-47D7-8FB0-3005260125FC Q31037300-D948A4CB-778F-43D6-9978-7DDEB7AA9848 Q33725030-812B2DFD-E604-4B6C-AA60-D6FAC7A5CE55 Q33909980-2023CE40-53C1-4FF9-98FF-47A377D474AC Q33909996-30C1ED27-2BD7-4425-8619-38E60658076D Q34057466-5874FBD5-5DBE-48EF-BE10-51551BE5BA73 Q34853625-339E0E47-DCAD-4E05-B822-8524F0D7F61B Q34977413-1A04D32D-50C5-4D75-B70C-AD4233D9E1D2 Q35102702-6E0CB9E3-3BD4-4482-9A4C-8ACBDCC77BDE Q35288691-6686AA87-E385-48DD-8A75-8A75755EFB78 Q35408073-FBDA4675-36A5-4B48-8F16-0DAEC8F52268 Q35547723-3F6AB271-D224-4DA5-9CD9-0C032758D696 Q35706069-2B503D07-65F9-4BE0-B558-CA34792BDC81 Q35802412-193925F6-73D4-4437-9F56-EEB13DF18DEB Q35846143-99314470-FCC9-4A2D-9373-968F176EA0CE Q35908584-119B9EA1-F865-4E8E-9F09-3E06E1217C6D Q35910664-D360903E-5331-40B2-BCED-A26C5EC54BAC Q35974648-C8A71888-90B6-4E0B-A942-398C16B6F243 Q36105822-138FF5B8-7194-4CA9-BD54-2B90A18BB190 Q36290009-ADDB427F-8EE5-4510-A36D-EC19D887B030 Q36437792-F61B0EC6-A647-49C4-8AD7-E77E9929514B Q36463979-5A282334-3135-4A47-8E69-18E3EDC0A90C Q36478066-B8B36E73-2CF0-43BE-9AB1-0C1A45D9A22E Q36554279-C0781CF6-B4A8-41C6-8126-CB6034677A1B Q36650954-AB2BBEFE-3DC1-49CA-A32B-C9EFA2B8CABA Q36657589-36DB36AD-CE49-466F-8005-B33F21908819 Q36717150-FC428CED-E012-4407-BB79-1D0D7E2FF611 Q36801543-0FDC4A05-928A-4124-8A97-C48BDE533499 Q36966640-2382BAA3-74B7-4CBF-B555-9E8A38B52AD6 Q37026878-1793D921-8939-46A1-A5E7-FB9B17107093 Q37030715-3C1B5748-BBE3-4F01-8089-52C679CF9759 Q37036991-130D2B3D-E658-4687-9D2D-28AFD7F0FC9E Q37037070-AE5B0463-258C-4A3E-BEF6-6A7EB6B28BAF Q37429325-4596D9FF-FDAF-47B0-BE39-927A4FE6DBA9 Q37617319-62890E03-0FA4-42DA-8CB5-2EF1EEE22C39 Q38124394-59467E90-0EB8-42BA-94AE-27BCE54BB451 Q38192688-E567C9D9-8B6A-4172-BF82-28C815E56345 Q38782609-D483037F-FF12-47B2-BF15-64029E7F097B Q38973113-1B0AA637-D4AF-4DA7-9084-532D3AA74571

P2860

Genome-wide association study of plasma efavirenz pharmacokinetics in AIDS Clinical Trials Group protocols implicates several CYP2B6 variants

http://www.wikidata.org/entity/Q36734592

description

2012 nî lūn-bûn

@nan

2012年の論文

@ja

2012年論文

@yue

2012年論文

@zh-hant

2012年論文

@zh-hk

2012年論文

@zh-mo

2012年論文

@zh-tw

2012年论文

@wuu

2012年论文

@zh

2012年论文

@zh-cn

name

Genome-wide association study ...... icates several CYP2B6 variants

@ast

Genome-wide association study ...... icates several CYP2B6 variants

@en

type

label

Genome-wide association study ...... icates several CYP2B6 variants

@ast

Genome-wide association study ...... icates several CYP2B6 variants

@en

prefLabel

Genome-wide association study ...... icates several CYP2B6 variants

@ast

Genome-wide association study ...... icates several CYP2B6 variants

@en

P1433

Q36734592-1256E6FB-3FDD-49BF-82D9-A158F43D7575

P1476

Q36734592-FA68EF31-242E-4453-B43F-0D062EF45EB9

P2093

Q36734592-1EE5A90C-85BB-428C-AC89-6439378400CD

Q36734592-60458850-A746-458D-8A60-6AF906187369

Q36734592-621574BF-5720-4F76-AB1A-09E989D9F95F

Q36734592-85FFA492-659D-429B-A874-6B90F8C99536

Q36734592-A17C152A-FCB6-4F76-A0AA-45735600FE5F

Q36734592-C5C61144-A8BF-4604-BBB1-E66063955209

Q36734592-C8AD5E5E-82B5-4985-83B6-BE8E65B1D0D3

Q36734592-C9BC2AED-D59F-4C33-B89C-809C4F689146

Q36734592-CC0FFB23-ACE4-4AF0-8A35-419D2E412573

Q36734592-E2B4A57A-2C75-4AA0-A6CF-DF3886D08839

P2860

Q36734592-011A0776-D4BB-4295-8A26-A5EFA6F6315F

Q36734592-021C9DE0-3623-4E5E-9E1F-9B6086773853

Q36734592-04500A7C-1335-4F7D-A23D-1C0E1A64B793

Q36734592-21F38BF7-7C49-4E2E-BA12-95335ADFAD15

Q36734592-27F15ED2-D376-473E-909E-3893655A64B4

Q36734592-28C210E1-017D-4331-B1A4-806C01743603

Q36734592-3AFB97AA-EF9D-4967-954D-F24C7BF90B6E

Q36734592-49F8BC09-F744-4F91-A8A6-0C7224EA12AB

Q36734592-4FB6496F-FF36-4750-81FE-94B1567B492D

Q36734592-553D5CFE-D529-44A7-8FE4-FC86984F4EE2

P304

Q36734592-3F33EF3B-7C43-49CB-9860-23734DE3F1A6

P31

Q36734592-8B53268A-AFB4-41D5-A311-8668859F4034

P356

Q36734592-4DA1323F-CF7B-4395-B79F-0E086522614C

P433

Q36734592-E23229F4-A7CD-4FDB-9F13-2E15A271580C

P478

Q36734592-F7783358-2FD1-488D-8A7F-47D07A0E557D

P50

Q36734592-86634194-D5C3-43C0-B1CB-FCC2C7D2B37C

Q36734592-F2EE5CBD-2C2B-4C1A-B98C-B49CE705EFC5

P577

Q36734592-0795D329-9C5D-4E1A-B596-33F4B292F857

P698

Q36734592-C9C0CACF-0DDD-4D9A-B6EC-3913EB73C36A

P921

Q36734592-7E509994-36AB-4F03-B547-9AC953106937

P932

Q36734592-A047447E-BE14-4F8F-A4B5-550C78BCC8A1

P356

FPC.0B013E32835A450B

P1433

Pharmacogenetics and Genomics

P1476

Genome-wide association study ...... icates several CYP2B6 variants

@en

P2093

Benjamin Grady

http://www.w3.org/2001/XMLSchema#string

David B Clifford

http://www.w3.org/2001/XMLSchema#string

David W Haas

http://www.w3.org/2001/XMLSchema#string

Edward P Acosta

http://www.w3.org/2001/XMLSchema#string

Emily R Holzinger

http://www.w3.org/2001/XMLSchema#string

Eric S Daar

http://www.w3.org/2001/XMLSchema#string

Gene D Morse

http://www.w3.org/2001/XMLSchema#string

Gregory K Robbins

http://www.w3.org/2001/XMLSchema#string

Heather J Ribaudo

http://www.w3.org/2001/XMLSchema#string

Roy M Gulick

http://www.w3.org/2001/XMLSchema#string

P2860

Population structure and eigenanalysis

CYP2B6, CYP2A6 and UGT2B7 genetic polymorphisms are predictors of efavirenz mid-dose concentration in HIV-infected patients

Effect of CYP2B6, ABCB1, and CYP3A5 polymorphisms on efavirenz pharmacokinetics and treatment response: an AIDS Clinical Trials Group study

PLINK: a tool set for whole-genome association and population-based linkage analyses

Principal components analysis corrects for stratification in genome-wide association studies

The major genetic determinants of HIV-1 control affect HLA class I peptide presentation.

Predictive value of known and novel alleles of CYP2B6 for efavirenz plasma concentrations in HIV-infected individuals.

A multi-investigator/institutional DNA bank for AIDS-related human genetic studies: AACTG Protocol A5128.

Abacavir-lamivudine versus tenofovir-emtricitabine for initial HIV-1 therapy

Population pharmacokinetics and pharmacodynamics of efavirenz, nelfinavir, and indinavir: Adult AIDS Clinical Trial Group Study 398.

P304

858-867

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1097/FPC.0B013E32835A450B

http://www.w3.org/2001/XMLSchema#string

P433

12

http://www.w3.org/2001/XMLSchema#string

P478

22

http://www.w3.org/2001/XMLSchema#string

P50

Marylyn D. Ritchie

Paul J. McLaren

P577

2012-12-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

23080225

http://www.w3.org/2001/XMLSchema#string

P921

genome-wide association study

P932

3614365

http://www.w3.org/2001/XMLSchema#string